Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer
Status:
Completed
Trial end date:
2014-01-29
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and the best dose of lenalidomide when given
together with cetuximab in treating patients with colorectal cancer or head and neck cancer
that has spread to other places in the body and usually cannot be cured or controlled with
treatment. Biological therapies, such as lenalidomide, use substances made from living
organisms that may stimulate the immune system in different ways and stop tumor cells from
growing. Monoclonal antibodies, such as cetuximab, may block tumor growth in different ways
by targeting certain cells. Giving lenalidomide together with cetuximab may be a better
treatment for colorectal cancer or head and neck cancer.